Taysha Gene Therapies Gains Momentum as Wells Fargo Raises Target on Rett Syndrome Program
Wells Fargo boosts its price target for Taysha Gene Therapies (TSHA), citing strong progress in its pivotal Rett syndrome gene therapy program. The company has dosed the first patient in a key trial phase and received FDA alignment on its regulatory pathway.